Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
535
datasets available to search
ShareScore release 0.9.0
Dataset results
535 results for “Neovascularization”
Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial Intelligence
ClinicalTrials.gov study NCT05208931. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
ClinicalTrials.gov study NCT03893474. IPD Sharing: NO. Countries: 1. Publications: 2.
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
ClinicalTrials.gov study NCT01350323. IPD Sharing: Not stated. Countries: 1. Publications: 3.
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TA
ClinicalTrials.gov study NCT04597632. IPD Sharing: YES. Countries: 16. Publications: 0.
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
ClinicalTrials.gov study NCT00618644. IPD Sharing: Not stated. Countries: 1. Publications: 7.
VEGF and PEDF in Patients With Myopic Choroidal Neovascularization
ClinicalTrials.gov study NCT02175940. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
ClinicalTrials.gov study NCT03324542. IPD Sharing: NO. Countries: 1. Publications: 1.
Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
ClinicalTrials.gov study NCT00645697. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT01033721. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Quantitative analysis of optical coherence tomography for neovascular age-related macular degeneration using deep learning
Open the record for dataset details and reuse information.
Predicting incremental and future visual change in neovascular age-related macular degeneration using deep learning
Open the record for dataset details and reuse information.
Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation
Open the record for dataset details and reuse information.
Data from: Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD
Open the record for dataset details and reuse information.
Data Set to: Effects of TNFα receptor TNF-Rp55- or TNF-Rp75- deficiency on corneal neovascularization and lymphangiogenesis in the mouse
<p>Data Set to: <strong>Effects of TNFα receptor TNF-Rp55- or TNF-Rp75- deficiency on corneal neovascularization and lymphangiogenesis in the mouse</strong></p> <p>Raw data and image files</p>
Insights from survival analyses during 12 years of anti-VEGF therapy for neovascular age-related macular degeneration
<p><b>Importance</b>: While multiple imputation models for missing data and use of mixed effects models generally provide better outcome estimates than using only observed data or last observation carried forward in clinical trials, such approaches usually cannot be applied to visual outcomes from retrospective analyses of clinical practice settings, so-called real-world outcomes.</p> <p><b>Objective: </b>To<b> </b>explore potential utility of survival analysis techniques for retrospective clinical practice visual outcomes.</p> <p><b>Design</b>: Retrospective cohort study with 12-year observation period.</p> <p><b>Setting: </b>A tertiary eye center.</p> <p><b>Participants</b>: Of 10,744 eyes with neovascular AMD receiving anti-VEGF therapy between October 2008 and February 2020, 7802 eyes met study criteria (treatment-naïve, first-treated eyes starting anti-VEGF therapy).</p> <p><b>Main outcome measures</b>: Kaplan-Meier estimates and Cox proportional hazards modelling were used to consider: VA reaching ETDRS (Early Treatment Diabetic Retinopathy Study) letter score 70 (Snellen equivalent 20/40) or better; duration VA sustained at or better than 70 (20/40); and VA declining to 35 (20/200) or worse.</p> <p><b>Results</b>: The median time to attaining VA letter score ≥ 70 (20/40) was 2.0 years (95% CI 1.87 - 2.32) after the first anti-VEGF injection. Predictive features were baseline VA (HR 1.43 per 5 ETDRS letter score or 1 line [95% CI 1.40 - 1.46]), baseline age (HR 0.88 per 5 years [95% CI 0.86 - 0.90]), and injection number (HR 1.123 [95% CI 1.101 - 1.15]). Of the 56% attaining this outcome, median time sustained at 70 (20/40) or better was 1.1 years (95% CI 1.1 - 1.2).</p> <p><b>Conclusions and relevance</b>: Survival analysis potentially addresses key limitations of retrospective clinical practice (real-world) data by accounting for variable observation time-points and follow-up durations. Modelling with multiple covariates reveals factors that may help inform the likely visual trajectory of an individual. We demonstrate the utility of our proposed analyses by showing that patients with neovascular AMD beginning anti-VEGF therapy are more likely to experience positive visual outcomes within the first 2.9 years, typically maintaining this for 1.1 years, but then deteriorating to poor vision within 8.7 years. We believe that this dataset, combined with our statistical approach for retrospective analyses, may provide long-term prognostic information for patients newly diagnosed with this condition.<a name="_nckpxvmwyi"></a></p>
Data from: The Moorfields AMD database report 2 - fellow eye involvement with neovascular age-related macular degeneration
<p><b>Background/Aims:</b> Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes'' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.</p> <p><b>Methods:</b> Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes.</p> <p><b>Results: </b>Mean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.</p> <p><b>Conclusion:</b> This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.</p>
Astrocytic Expression of Yes-Associated Protein (YAP) Regu-lates Retinal Neovascularization in a Mouse Model of Oxy-gen-Induced Retinopathy
<p>Original images used for each figure.</p>
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT03313401. IPD Sharing: NO. Countries: 0. Publications: 3.
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT01134055. IPD Sharing: Not stated. Countries: 9. Publications: 0.
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
ClinicalTrials.gov study NCT05275205. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.